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Key findings
Data from the National 
Health and Nutrition 
Examination Survey
 ● The prevalence of any past 
or present hepatitis B virus 
(HBV) infection was 4.3%, and 
was higher among men (5.3%) 
than women (3.4%).
 ● Past or present HBV 
infection was highest among 
non-Hispanic Asian adults 
(21.1%) compared with 
non-Hispanic white (2.1%), 
non-Hispanic black (10.8%), 
and Hispanic (3.8%) adults, and 
was greater among adults born 
outside of the United States 
than those who were U.S. born. 
 ● The prevalence of hepatitis 
B vaccination, based on 
blood test results, was 25.2%, 
and was highest among 
non-Hispanic Asian adults 
compared with non-Hispanic 
white, non-Hispanic black, and 
Hispanic adults. 
 ● From 1999 through 2018, 
the prevalence of past or 
present infection decreased 
from 5.7% to 4.3%; evidence 
of vaccination increased from 
12.3% to 25.2%.
Hepatitis B virus (HBV) is a type of viral hepatitis transmitted through sexual 
contact, contaminated blood, or from an infected mother to her newborn (1). 
HBV may cause a liver infection that is acute or short-term, but may also 
cause chronic or long-term infection. Vaccination was targeted to high-risk 
groups in 1982, and universal vaccination of newborns was recommended 
beginning in 1991 in the United States (2). This report provides 2015–2018 
prevalence estimates of past or present HBV infection and evidence of 
hepatitis B vaccination, based on blood collected in the National Health and 
Nutrition Examination Survey (NHANES).
Did the prevalence of any past or present HBV infection 
differ by sex, race and Hispanic origin, or U.S. birth status?
During 2015–2018, the prevalence of any past or present HBV infection was 
4.3% among adults aged 18 and over (Figure 1).
1Significantly different from women.
2Significantly different from non-Hispanic black persons.
3Significantly different from non-Hispanic Asian persons.
4Significantly different from Hispanic persons.
5Significantly different from U.S.-born persons.
NOTES: The presence of antibody to hepatitis B core antigen is evidence of past or present infection. Percentages are age 
adjusted by the direct method to the 2000 projected U.S. population using age groups 20–29, 30–39, 40–49, 50–59, 
and 60 and over. U.S. born includes persons born within the 50 United States and the District of Columbia. Access data table 
for Figure 1 at: https://www.cdc.gov/nchs/data/databriefs/db361-tables-508.pdf#1. 
SOURCE: NCHS, National Health and Nutrition Examination Survey, 2015–2018.
Figure 1. Age-adjusted prevalence of past or present hepatitis B virus infection among adults aged 
18 and over, by sex, race and Hispanic origin, and U.S. birth status: United States, 2015–2018
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Prevalence was higher among men (5.3%) compared with women (3.4%).
Prevalence was highest among non-Hispanic Asian adults (21.1%), followed by non-Hispanic 
black (10.8%), Hispanic (3.8%), and non-Hispanic white (2.1%) adults.
Prevalence was higher among those born outside of the United States (11.9%) compared with 
those who were U.S. born (2.5%).
Did the prevalence of hepatitis B vaccination differ by sex, race and 
Hispanic origin, or U.S. birth status?
During 2015–2018, the prevalence of hepatitis B vaccination, based on blood test results, was 
25.2% among adults aged 18 and over (Figure 2).
Prevalence was higher among women (28.1%) compared with men (22.0%).
Prevalence was highest among non-Hispanic Asian adults (31.4%), followed by non-Hispanic 
white (26.6%), non-Hispanic black (23.2%), and Hispanic (19.9%) adults.
The prevalence of hepatitis B vaccination did not differ significantly by U.S. birth status.
1Significantly different from women.
2Significantly different from non-Hispanic black persons.
3Significantly different from non-Hispanic Asian persons.
4Significantly different from Hispanic persons.
NOTES: The presence of antibody to hepatitis B surface antigen but absence of antibody to hepatitis B core antigen is evidence of hepatitis B vaccination. 
Percentages are age adjusted by the direct method to the 2000 projected U.S. population using age groups 20–29, 30–39, 40–49, 50–59, and 60 and over. 
U.S. born includes persons born within the 50 United States and the District of Columbia. Access data table for Figure 2 at: https://www.cdc.gov/nchs/data/
databriefs/db361-tables-508.pdf#2. 
SOURCE: NCHS, National Health and Nutrition Examination Survey, 2015–2018.
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Figure 2. Age-adjusted prevalence of serologic evidence of hepatitis B vaccination among adults aged 18 and over, 
by sex, race and Hispanic origin, and U.S. birth status: United States, 2015–2018
NCHS Data Brief ■ No. 361 ■ March 2020
■  3  ■
What was the trend in the prevalence of any past or present HBV infection? 
The prevalence of past or present HBV infection decreased over time from 5.7% during 
1999–2002 to 4.3% during 2015–2018 (Figure 3).
Figure 3. Trends in the age-adjusted prevalence of past or present hepatitis B virus infection among adults aged 18 and 
over: United States, 1999–2018
1Significant linear decline over time for any past or present hepatitis B virus infection (p < 0.05).
NOTES: All values meet National Center for Health Statistics presentation standards. The presence of antibody to hepatitis B core antigen is evidence of past or 
present infection. Percentages are age adjusted by the direct method to the 2000 projected U.S. population using age groups 20–29, 30–39, 40–49, 50–59, and 60 
and over. Access data table for Figure 3 at: https://www.cdc.gov/nchs/data/databriefs/db361-tables-508.pdf#3.
SOURCE: NCHS, National Health and Nutrition Examination Survey, 1999–2018.
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What was the trend in the prevalence of hepatitis B vaccination? 
The prevalence of hepatitis B vaccination, based on blood test results, increased over time from 
12.3% during 1999–2002 to 25.2% during 2015–2018 (Figure 4).
Figure 4. Trends in the age-adjusted prevalence of serologic evidence of hepatitis B vaccination among adults  
aged 18 and over: United States, 1999–2018 
1Significant linear increase over time for hepatitis B virus vaccination (p < 0.05).
NOTES: The presence of antibody to hepatitis B surface antigen but absence of antibody to hepatitis B core antigen is evidence of hepatitis B vaccination. 
Percentages are age adjusted by the direct method to the 2000 projected U.S. population using age groups 20–29, 30–39, 40–49, 50–59, and 60 and over. 
Access data table for Figure 4 at: https://www.cdc.gov/nchs/data/databriefs/db361-tables-508.pdf#4.
SOURCE: NCHS, National Health and Nutrition Examination Survey, 1999–2018.
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Summary 
The prevalence of any past or present HBV infection during 2015–2018 was 4.3%. Prevalence 
was higher among men (5.3%) compared with women (3.4%), and was highest among 
non-Hispanic Asian adults (21.1%), followed by non-Hispanic black adults (10.8%). Adults who 
were born outside of the 50 United States and the District of Columbia had a higher prevalence 
of past or present infection (11.9%) compared with those born in the United States (2.5%). These 
results are consistent with prior literature on HBV infection by race and ethnicity and birth 
status (3–5). 
The prevalence of hepatitis B vaccination, based on blood test results, was 25.2%. Prevalence 
was higher among women (28.1%) compared with men (22.0%), and higher among non-Hispanic 
Asian adults (31.4%) compared with adults from all other race and Hispanic-origin subgroups. 
Vaccination status did not differ significantly by U.S. birth status. 
There was a significant decreasing trend over time in past or present infection from 1999–2002 
(5.7%) through 2015–2018 (4.3%). This decrease corresponds to an increasing trend during the 
same time period in hepatitis B vaccination based on blood test results. Prevalence among adults 
was 12.3% during 1999–2002 and increased to 25.2% during 2015–2018. 
NHANES sample does not include certain groups, such as institutionalized, incarcerated, and 
homeless persons. There may be a higher prevalence of risk behaviors and need for adult hepatitis 
B vaccination among some of these populations (e.g., injection-drug users). Therefore, the data 
in this report may provide conservative estimates of the overall prevalence of infection and 
vaccination.
Definitions
Prevalence of past or present HBV infection: Presence of antibody to hepatitis B core antigen.
Prevalence of hepatitis B vaccination: Based on blood test results, the presence of antibody to 
hepatitis B surface antigen (anti-HBs) but absence of antibody to hepatitis B core antigen. There 
are limitations to this marker for vaccination. Because anti-HBs may wane during the years 
following vaccination, not all vaccinated persons will have anti-HBs; however, protection may 
persist because immune memory remains intact (6).
U.S. birth status: Participants who were born in the 50 United States or the District of Columbia 
were categorized as U.S. born. Those who were born outside of the United States were 
categorized as non-U.S. born.
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Data source and methods
Data from the 1999–2018 NHANES were used for these analyses. NHANES is a cross-sectional 
survey designed to monitor the health and nutritional status of the civilian, noninstitutionalized 
U.S. population. The survey consists of interviews conducted in participants’ homes, followed 
by standardized physical examinations that include collection of blood and other biological 
specimens for laboratory testing. Hepatitis B estimates are based on the laboratory testing 
of blood samples that are collected when a participant is examined in the NHANES mobile 
examination center.
NHANES is based on a complex, multistage design with data released in 2-year cycles. The 
design includes oversampling and the ability to combine cycles to obtain reliable estimates for 
population subgroups. Starting with the 2007–2008 survey cycle, all Hispanic persons, and 
starting with the 2011–2012 survey cycle, non-Hispanic Asian persons, were oversampled to 
obtain more reliable estimates of health for these racial and ethnic groups. Additional information 
about NHANES is available from: https://www.cdc.gov/nchs/nhanes.htm.
Prevalence estimates and standard errors were calculated in SAS-callable SUDAAN software 
release 11.0 (RTI International, Research Triangle Park, N.C.) and Stata15 (StataCorp, College 
Station, Tex.). The examination sample weights were used to account for differing probabilities 
of selection, nonresponse, and noncoverage. Taylor series linearization was used to calculate 
standard errors to account for the complex sampling design. Differences between groups were 
evaluated using Student’s t statistic at the p < 0.05 significance level. Tests for trends were 
conducted using an orthogonal polynomial contrast procedure in SUDAAN. All estimates in this 
report meet National Center for Health Statistics standards of reliability as specified in “National 
Center for Health Statistics Data Presentation Standards for Proportions” (7). All differences 
discussed are statistically significant unless otherwise indicated. Calculated estimates were age 
adjusted by the direct method to the 2000 projected U.S. population using age groups 20–29, 
30–39, 40–49, 50–59 and 60 and over. No adjustments were made for multiple comparisons. 
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